Zobrazeno 1 - 10
of 327
pro vyhledávání: '"Yayoi Tada"'
Autor:
Yukari Okubo, Tadashi Terui, Satomi Kobayashi, Shigetoshi Sano, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Masafumi Yaguchi, Takeshi Kimura, Junichiro Shimauchi, Wendy Zhang, Hamid Amouzadeh, Masamoto Murakami
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1863-1873 (2024)
Abstract Introduction Palmoplantar pustulosis (PPP) is a pruritic, painful, chronic dermatitis that greatly impacts functioning and quality of life and can be difficult to treat. Approved treatment options for PPP are limited, and many patients do no
Externí odkaz:
https://doaj.org/article/34a2089061c64c6f827972a89c82714f
Autor:
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, Ryuta Sakuma, Luis Puig, Matthew Davis, Dominic Nunag, Andreas Pinter, Shinichi Imafuku
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 99-114 (2023)
Abstract Introduction Patients with moderate-to-severe psoriasis (PsO) treated with interleukin (IL)-inhibitors may require treatment modification to achieve disease control. This study evaluated discontinuation and switching of IL-inhibitors for PsO
Externí odkaz:
https://doaj.org/article/c7c766b9c1614705a27a88d773493cf3
Autor:
Makoto Ito, Masahiro Kamata, Hideaki Uchida, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 168-171 (2023)
Abstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupil
Externí odkaz:
https://doaj.org/article/4b139843692745c887fbbfb2d450e943
Autor:
Makoto Ito, Masahiro Kamata, Takeko Ishikawa, Hideaki Uchida, Shoya Suzuki, Ryosuke Takeshima, Ayu Watanabe, Itsumi Mizukawa, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 152-158 (2023)
Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medica
Externí odkaz:
https://doaj.org/article/bf8f9473143e4fcba7849cbbc62924ca
Autor:
Akimichi Morita, Yukari Okubo, Shinichi Imafuku, Yayoi Tada, Keiichi Yamanaka, Kazumitsu Sugiura, Yukie Yamaguchi, Masahito Yasuda, Hitoshi Tsuchihashi, Morihisa Saitoh, Wataru Sakamoto, Ryuhei Okuyama, the study investigators
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 2, Pp 261-272 (2023)
Abstract Background Generalized pustular psoriasis (GPP) is a rare and often refractory disease, and GPP flares can be life threatening. The rarity of GPP prevents the development and evaluation of effective GPP‐specific treatments and obstructs di
Externí odkaz:
https://doaj.org/article/318927d3bab444da8a4fed58d243b566
Autor:
Chika Ohata, Yasumasa Kanai, Kenta Murotani, Fumikazu Yamazaki, Hidetoshi Takahashi, Yayoi Tada, Tomotaka Mabuchi, Yoko Mizutani, Takanobu Nomura, Shinichi Imafuku
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 1039-1052 (2023)
Abstract Introduction Evidence on treatment effectiveness in patients with psoriasis having anxiety or depressive symptoms helps shared decision-making. This single-arm, open-label, prospective study—ProLOGUE—was conducted to assess the effective
Externí odkaz:
https://doaj.org/article/189c7d8b668b46d48d4cc61c8e3ae087
Autor:
Masahiro Kamata, Yayoi Tada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In the past, psoriasis was considered a skin disease caused only by keratinocyte disorders. However, the efficacy of immunosuppressive drugs and biologics used to treat psoriasis proves that psoriasis is an immune-mediated disease. Indeed, a variety
Externí odkaz:
https://doaj.org/article/dd77b48dfbac4508865896f274505c07
Autor:
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G. Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 3, Pp 751-768 (2023)
Abstract Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the BE
Externí odkaz:
https://doaj.org/article/d03aa7955b37400c8563d4be5e6ba857
Autor:
Masahiro Kamata, Yayoi Tada
Publikováno v:
JID Innovations, Vol 3, Iss 3, Pp 100195- (2023)
Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can
Externí odkaz:
https://doaj.org/article/3def8078a9a348b08b547b7e2914d036
Autor:
Hideaki Uchida, Masahiro Kamata, Shota Egawa, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 5, Iss 1, Pp 17-21 (2022)
Abstract Dupilumab demonstrated high efficacy and tolerable safety profiles in moderate‐to‐severe atopic dermatitis (AD) patients in clinical trials; however, certain patients suffer from facial redness, while obtaining good responses on the trun
Externí odkaz:
https://doaj.org/article/4ff8145c25d9420e8d0dbf8c5954eff7